| Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 |
ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs' Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Micro Labs has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. |
globenewswire.com |
2025-05-12 12:00:00 |
Czytaj oryginał (ang.) |
| Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference |
ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET. |
globenewswire.com |
2025-05-09 12:00:00 |
Czytaj oryginał (ang.) |
| Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. |
globenewswire.com |
2025-05-08 20:30:00 |
Czytaj oryginał (ang.) |
| Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada |
– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians Living with Diagnosed Heart Disease – ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with HLS Therapeutics (TSX:HLS) for the exclusive rights to commercialize NEXLETOL* and NEXLIZET* in Canada. |
globenewswire.com |
2025-05-08 10:30:00 |
Czytaj oryginał (ang.) |
| ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down |
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. |
zacks.com |
2025-05-07 17:10:36 |
Czytaj oryginał (ang.) |
| Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript |
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Chief Executive Officer Ben Halladay - Chief Financial Officer Betty Jean Swartz - Chief Business Officer Conference Call Participants Dennis Ding - Jefferies Joseph Pantginis - H.C. Wainwright Jason Zemansky - Bank of America Kristen Kluska - Cantor Fitzgerald Jessica Fye - J.P. |
seekingalpha.com |
2025-05-06 14:49:25 |
Czytaj oryginał (ang.) |
| Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates |
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to earnings of $0.34 per share a year ago. |
zacks.com |
2025-05-06 12:15:35 |
Czytaj oryginał (ang.) |
| Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for |
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-29 15:06:30 |
Czytaj oryginał (ang.) |
| Esperion to Participate in The Citizens Life Sciences Conference |
ANN ARBOR, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET. |
globenewswire.com |
2025-04-25 12:00:00 |
Czytaj oryginał (ang.) |
| 5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms |
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio. |
zacks.com |
2025-04-23 14:35:35 |
Czytaj oryginał (ang.) |
| Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
Esperion Therapeutics (ESPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2025-04-22 14:36:03 |
Czytaj oryginał (ang.) |
| Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025 |
Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases |
globenewswire.com |
2025-04-10 12:00:00 |
Czytaj oryginał (ang.) |
| Esperion Appoints Robert E. Hoffman to Board of Directors |
- Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Robert E. |
globenewswire.com |
2025-04-01 12:00:00 |
Czytaj oryginał (ang.) |
| ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia |
Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia. |
zacks.com |
2025-03-21 12:30:28 |
Czytaj oryginał (ang.) |
| ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y |
Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates. |
zacks.com |
2025-03-05 11:50:36 |
Czytaj oryginał (ang.) |
| Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript |
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Chief Executive Officer Ben Halladay - Chief Financial Officer Eric Warren - Chief Commercial Officer Conference Call Participants Dennis Ding - Jefferies Joseph Pantginis - H.C. Wainwright Thomas Shrader - BTIG Tanmay Patwardhan - JPMorgan Jason Zemansky - Bank of America Serge Belanger - Needham Paul Choi - Goldman Sachs Kristen Kluska - Cantor Fitzgerald Operator Ladies and gentlemen, thank you for standing by, and welcome. |
seekingalpha.com |
2025-03-04 12:34:30 |
Czytaj oryginał (ang.) |
| Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates |
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.50 per share a year ago. |
zacks.com |
2025-03-04 10:10:30 |
Czytaj oryginał (ang.) |
| Esperion Reports Fourth Quarter and Full Year 2024 Financial Results |
– FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million – |
globenewswire.com |
2025-03-04 08:00:00 |
Czytaj oryginał (ang.) |
| Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia |
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales – – Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales – |
globenewswire.com |
2025-03-03 10:00:00 |
Czytaj oryginał (ang.) |
| Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know |
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-25 13:00:30 |
Czytaj oryginał (ang.) |
| Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4 |
ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025. |
globenewswire.com |
2025-02-18 10:00:00 |
Czytaj oryginał (ang.) |
| Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
ANN ARBOR, Mich., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 11, 2025, the Company granted ten new employees 58,300 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. |
globenewswire.com |
2025-02-13 18:30:00 |
Czytaj oryginał (ang.) |
| Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions |
– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt – |
globenewswire.com |
2024-12-18 09:00:00 |
Czytaj oryginał (ang.) |
| Esperion Announces $210 Million Convertible Debt Financing |
ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the “Agreements”) with certain holders of its outstanding 4.00% Convertible Senior Subordinated Notes due 2025 (the “2025 Notes”). Pursuant to the Agreements, Esperion will issue $100 million aggregate principal amount of its 5.75% Convertible Senior Subordinated Notes due 2030 (the “New Notes”) consisting of (a) approximately $57.5 million principal amount of New Notes, along with approximately $153.4 million in cash, issued in exchange for approximately $210.1 million principal amount of the 2025 Notes (the “Exchange Transactions”) and (b) approximately $42.5 million principal amount of New Notes for cash (the “Subscription Transactions”), in each case, pursuant to exemptions from registration under the Securities Act of 1933, as amended (the “Securities Act”). |
globenewswire.com |
2024-12-13 08:00:00 |
Czytaj oryginał (ang.) |
| Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel |
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales – – Israel-Based Commercial Organization Brings Successful Track Record Commercializing Pharmaceutical Products for More Than 80 Years – ANN ARBOR, Mich., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel. |
globenewswire.com |
2024-12-12 10:00:00 |
Czytaj oryginał (ang.) |
| Will The Long Awaited Breakout For Esperion Therapeutics Hold? |
Esperion Therapeutics' stock broke out above a year-long trading range, signaling a potential sustainable breakout if support at $3.40 holds. Despite past skepticism and price fades, recent technical achievements and strategic moves, including global drug submissions, bolster the stock's outlook. The Piper Sandler Conference reinforced Esperion's growth strategy, with CEO Sheldon Koenigand CFO Ben Halladay providing encouraging news on guidance and business performance. |
seekingalpha.com |
2024-12-08 09:43:11 |
Czytaj oryginał (ang.) |
| ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada |
Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and cardiovascular risk. Shares rise. |
zacks.com |
2024-12-03 13:10:19 |
Czytaj oryginał (ang.) |
| Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 |
– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo – |
globenewswire.com |
2024-11-18 12:30:00 |
Czytaj oryginał (ang.) |
| Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy |
I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization efforts, including market coverage expansion and sales force growth, have significantly boosted retail prescriptions and broadened future revenue streams. International expansion through partnerships with Daiichi Sankyo Europe and Otsuka Pharmaceutical has driven prescription and revenue growth, strengthening ESPR's global presence. |
seekingalpha.com |
2024-11-13 04:08:21 |
Czytaj oryginał (ang.) |
| Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. |
globenewswire.com |
2024-11-08 18:15:00 |
Czytaj oryginał (ang.) |
| Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y |
ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates. |
zacks.com |
2024-11-07 14:00:37 |
Czytaj oryginał (ang.) |
| Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates |
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.37 per share a year ago. |
zacks.com |
2024-11-07 10:11:16 |
Czytaj oryginał (ang.) |
| Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update |
– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – |
globenewswire.com |
2024-11-07 08:00:00 |
Czytaj oryginał (ang.) |
| Esperion to Participate in Upcoming Jefferies London Healthcare Conference |
ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:30 a.m. ET. |
globenewswire.com |
2024-11-04 10:00:00 |
Czytaj oryginał (ang.) |
| Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release |
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-31 13:05:59 |
Czytaj oryginał (ang.) |
| Esperion to Report Third Quarter 2024 Financial Results on November 7 |
ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024. |
globenewswire.com |
2024-10-24 12:00:00 |
Czytaj oryginał (ang.) |
| Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) |
ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. |
globenewswire.com |
2024-09-25 20:30:00 |
Czytaj oryginał (ang.) |
| Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report? |
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-09-11 16:30:26 |
Czytaj oryginał (ang.) |
| Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) |
– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insured Lives – |
globenewswire.com |
2024-09-03 12:00:00 |
Czytaj oryginał (ang.) |
| Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference |
ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 8:30 a.m. ET. |
globenewswire.com |
2024-08-26 12:00:00 |
Czytaj oryginał (ang.) |
| Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs |
Meeting expectations with revenue growth, expense guidance, and sales execution. Potential overhang from financial engineering with complex deals, warrants, and generic litigants. Maintaining a buy rating for Esperion Therapeutics, Inc. based on current execution and expanding international scope. |
seekingalpha.com |
2024-08-19 13:10:11 |
Czytaj oryginał (ang.) |
| Esperion Therapeutics: Strategically Positioned To Grow |
Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving significant growth. Strong revenue growth and margin expansions reflect improving financial performance and market breakthrough. |
seekingalpha.com |
2024-08-16 08:09:08 |
Czytaj oryginał (ang.) |